Advertisement

Topics

Dravet Syndrome Treatment Granted Orphan Drug Designation by FDA

06:30 EDT 24 Aug 2017 | PharmPro

Epygenix Therapeutics receives U.S. FDA Orphan Drug designation for EPX-300 for the treatment of patients with Dravet Syndrome. It is a catastrophic form of epilepsy, affecting one in 15,700 children and adults in the United States.
Contributed Author: 
Epygenix Therapeutics, Inc.

Original Article: Dravet Syndrome Treatment Granted Orphan Drug Designation by FDA

NEXT ARTICLE

More From BioPortfolio on "Dravet Syndrome Treatment Granted Orphan Drug Designation by FDA"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...